Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Alabama now provides partial GLP-1 coverage for obesity: Among the obesity-indicated GLP-1s, Medicaid in Alabama covers just ...

The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For 2025, competition and supply constraints are areas to watch.

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

The holidays can be a difficult time for those with a history of eating disorders, and having someone comment on their body – ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

After about 10 months of being on Ozempic and working my way up to a 1-mg dose, I lost 40 pounds effortlessly. Sugar cravings ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

After about 10 months of being on Ozempic and working my way up to a 1-mg dose, I lost 40 pounds effortlessly. Sugar cravings disappeared as if by magic. I then noticed myself drifting backward and ...

Wegovy and Ozempic are the exact same drug: semaglutide. They are dosed slightly differently and marketed for different ...